Alexander W Clowes

Plain English
Researchers studied a genetic variation in a gene called p27 that controls cell growth, which previous studies linked to vein grafts failing after bypass surgery. They compared cells from different parts of the vein and found that people with the protective genetic variant had more p27 protein, which slowed the growth of outer vein cells but didn't affect the inner muscle cells. This matters because it identifies which part of the vein (the outer layer) is responsible for graft failure, pointing doctors toward new ways to prevent failed vein grafts by targeting growth in that specific layer.

Plain English
Researchers created a new 5-question survey called the Claudication Symptom Instrument to measure pain and other leg symptoms that people with intermittent claudication (a condition where leg pain occurs during walking) actually experience, based on what patients said mattered most to them. The survey reliably measures these symptoms when given multiple times, produces consistent results, and can detect when a patient's condition improves or worsens after treatment. This tool takes only 3 minutes to complete and could help doctors better track how their patients are doing during treatment.

Plain English
Dialysis grafts—artificial blood vessels used for kidney dialysis—often fail because a protein called tissue factor causes blood clots to form and scar tissue to build up inside the graft, narrowing it. Researchers found that tissue factor activity was significantly higher in the venous end of experimental grafts (where failure happens fastest) starting just 2 days after implantation and remaining high for at least 8 weeks. Blocking this protein could prevent graft failure and help millions of dialysis patients avoid repeated surgeries to replace failing access grafts.

Plain English
Researchers studied cells from vein grafts that either failed or remained healthy to understand why about 30% of vein grafts used in bypass surgery become blocked. They examined which genes were active in these cells and found two key genes—SCARA5 and SBSN—that appear linked to graft failure: blocking SCARA5 made cells grow faster, while blocking SBSN reduced the cells' ability to contract and remodel tissue. These findings matter because identifying the genes involved in vein graft failure could eventually lead to new treatments that prevent grafts from clogging, improving outcomes for bypass surgery patients.

Plain English
Surgeons use marking pens containing crystal violet dye on veins during bypass graft surgery to prevent the vein from twisting. Researchers tested whether this dye affects how well the vein heals after surgery by examining human veins marked with the dye compared to unmarked veins in the lab. The dye significantly slowed the growth and movement of cells in the outer layer of the vein—two processes critical for the vein to heal properly after being transplanted—but the dye didn't reach the inner layer so it didn't affect those cells. This finding matters because it suggests surgeons should find a different, safer way to mark veins during bypass surgery, since the current marking method may compromise how well the transplanted vein functions long-term.

Plain English
Researchers discovered that a chemical messenger called nitric oxide, produced by blood vessel cells, protects the body from weight gain and diabetes by converting inflammatory immune cells in the liver into anti-inflammatory ones. When mice were engineered to produce extra nitric oxide, they resisted the liver damage and insulin problems caused by a high-fat diet, because their immune cells stayed calm instead of becoming inflamed. The study shows that this nitric oxide pathway is essential for preventing the liver inflammation and diabetes that normally develop from eating high-fat diets.

Plain English
Researchers tested whether they could use gene therapy to prevent heart disease in veins used as bypass grafts, using rabbits as a model. They discovered that genes introduced immediately after surgery were quickly lost, but genes introduced 28 days after surgery—once the vein had adjusted to carrying arterial blood—remained active for at least 6 months. This matters because vein grafts used in heart surgery often fail within a few years due to atherosclerosis (plaque buildup), and a gene therapy approach timed correctly could potentially prevent this and extend how long the grafts work.

Plain English
Researchers discovered that a protein called VASP protects blood vessels from inflammation and insulin resistance—problems that commonly develop in obese people eating high-fat diets. When mice ate high-fat food, their VASP levels dropped dramatically, their blood vessels became inflamed, and their cells stopped responding properly to insulin; removing VASP entirely produced the same problems, while boosting VASP prevented them. This matters because VASP could be a new drug target to treat the dangerous blood vessel damage that comes with obesity, potentially reducing heart disease and diabetes risk without requiring weight loss.

Plain English
Researchers studied 56 patients who had leg bypass surgeries using their own veins and measured levels of a natural protective antibody in their blood before surgery. They found that patients with low levels of this antibody were 3.6 times more likely to have their grafts fail or become clogged within 18 months compared to those with higher levels. This matters because doctors could potentially use a simple blood test to identify high-risk patients before surgery, and the discovery might lead to new treatments that boost this antibody to prevent graft failure and help bypass surgeries last longer.

Plain English
Endurance athletes—particularly cyclists and runners—sometimes develop a condition where scar tissue builds up in an artery in the groin, causing severe leg pain during intense exercise that goes away when they stop. Researchers reviewed eight female athletes with this problem and discovered that the artery was also spasming (suddenly tightening) during exercise, which may be the primary cause of the pain rather than just the scar tissue itself. All eight athletes had surgery to repair the artery and returned to their sports without pain, suggesting that treating both the scarring and the spasms works.

Plain English
Researchers discovered that a protein called VASP helps the liver burn fat by turning on another protein called AMPK, which is known to prevent fat buildup in the liver. When mice lacked VASP, their livers accumulated excessive fat because they couldn't burn fatty acids properly, but restoring VASP reversed this problem by reactivating AMPK. This matters because fatty liver disease affects millions of people and contributes to diabetes and liver damage—this research identifies VASP as a potential drug target, and the study even showed that an existing drug (sildenafil) can activate VASP to reduce liver fat in diabetic mice.

Plain English
Researchers discovered that a cell surface receptor called syndecan-1 works with a protein called Topors to slow down cell growth and block a growth-promoting signal called PDGF-B. They found this by identifying where these two proteins bind together and then removing Topors from cells to see what happened. This matters because understanding how syndecan-1 puts the brakes on cell growth could lead to new treatments for diseases where cells grow out of control, like cancer.

Plain English
Researchers studied how a high-fat diet damages the liver's ability to respond to insulin, focusing on immune cells in the liver called Kupffer cells that become inflamed during high-fat feeding. They found that a chemical messenger called nitric oxide normally prevents these immune cells from becoming inflamed, but high-fat diets reduce nitric oxide levels in the liver, allowing harmful inflammation to develop. The researchers showed that boosting nitric oxide signaling protects against this inflammation and insulin resistance, while mice genetically lacking the ability to make nitric oxide developed liver inflammation even on a normal diet. This suggests that nitric oxide is the key chemical that normally keeps liver inflammation in check during high-fat feeding. This matters because it identifies a specific biological pathway that could be targeted with new drugs to prevent or treat fatty liver disease and diabetes caused by obesity.

Plain English
Researchers found that when mice eat a high-fat diet, blood vessels in their fat tissue lose the ability to produce a protective molecule called nitric oxide, which normally prevents inflammation. When this nitric oxide signaling breaks down, the fat tissue becomes inflamed and contributes to diabetes and insulin resistance. The team showed that boosting this nitric oxide pathway with an existing drug (sildenafil) blocked the inflammation and could potentially prevent or treat obesity-related diabetes.

Plain English
Researchers studied two different ways that blood vessels shrink and weaken—one caused by high blood flow through grafts and another caused by tight wrapping around arteries—and found that seven specific genes are activated in both situations. These activated genes produce enzymes that break down the structural material holding blood vessel cells together, and the researchers discovered that when vessel cells die, these same genes turn on, suggesting the body is deliberately dismantling the vessel's structure as the cells die. This discovery identifies specific genes that control how blood vessels deteriorate, which could eventually lead to new treatments to prevent or slow this dangerous weakening of blood vessels used in surgery.

Plain English
Researchers grew aneurysms (bulges in blood vessels) in rats and found that as the aneurysms expanded outward in diameter, the blood vessels also stretched longer—the two measurements stayed proportional during early growth. When the team tested treatments that slow aneurysm growth, they discovered that blocking certain destructive enzymes (called MMPs) also prevented the vessels from stretching longer, showing that the same biological process causes both the bulging and the lengthening. This matters because doctors currently only monitor aneurysm width to decide when surgery is needed; understanding that length changes too could help them better predict when an aneurysm will rupture and how treatments actually work.

Plain English
Researchers studied how a chemical messenger called nitric oxide changes the behavior of muscle cells in blood vessel walls by modifying a protein called VASP. They found that when nitric oxide phosphorylates (adds a chemical tag to) VASP at a specific location, it weakens the muscle cells' ability to contract and squeeze collagen fibers, while simultaneously making them more likely to invade surrounding tissue. This matters because these same processes go wrong in diseases like atherosclerosis and pulmonary hypertension, where abnormal muscle cell behavior damages blood vessels—so understanding how nitric oxide controls muscle cells through this VASP mechanism could lead to new treatments.

Plain English
Researchers studied a protein called syndecan-1 that sits on the surface of cells in blood vessel walls to understand whether it prevents dangerous thickening inside arteries after injury. They found that mice lacking this protein developed severe artery blockages after injury because their muscle cells multiplied out of control, while normal mice with the protein stayed healthy—suggesting syndecan-1 acts as a natural brake on cell growth. This discovery matters because it identifies a potential new target for preventing heart attacks and strokes caused by artery narrowing, or for improving treatments like stent placement.

Plain English
Researchers studied what happens when blood flows too fast through synthetic blood vessel grafts in baboons and found that high flow speeds up the death of muscle cells in the graft's inner lining while triggering the production of a protein-cutting enzyme called ADAMTS4. When they exposed muscle cells in the lab to a death-triggering signal, both the ADAMTS4 enzyme and cell death increased about five-fold, suggesting that this enzyme cuts up a structural protein called versican, which then causes the muscle cells to die and the graft tissue to shrivel. This matters because it could explain why artificial blood vessel grafts sometimes fail—understanding this death mechanism might lead to treatments that prevent the enzyme from destroying the graft or keep muscle cells alive longer.

Plain English
Researchers grew cells from vein grafts taken from 18 patients—11 whose grafts stayed healthy and 7 whose grafts narrowed—and tested how aggressively these cells multiplied when exposed to growth-triggering chemicals. Cells from grafts that failed grew much faster in response to these chemicals, and importantly, they ignored heparin (a drug that normally slows cell growth), while cells from successful grafts responded to it. This means some patients' vein graft cells are naturally more aggressive growers that resist treatment, which could explain why certain people's grafts fail while others succeed, and points to potential new ways to prevent graft failure by targeting these overgrown cells.

Plain English
Researchers studied 1,404 patients who had vein bypass surgery to save their legs from amputation due to blocked arteries, tracking their results for one year. They found that Black patients—especially Black women—had much higher rates of graft failure and limb loss compared to other groups, even after accounting for medical factors like age, smoking, and diabetes. The reasons for these differences aren't yet clear, but the findings suggest that race and gender significantly affect how well this surgery works, and Black women need special attention to improve their outcomes.

Plain English
Researchers grew blood vessel cells in the lab and modified some of them to produce a protein called biglycan without its normal sugar chains attached. These modified cells produced much more elastic fiber—the stretchy material that makes blood vessels flexible—compared to unmodified cells, while producing less collagen, the stiff structural protein. When they implanted these modified cells into injured blood vessels in rats, the resulting scar tissue contained more elastic fibers arranged in organized patterns, similar to healthy vessel tissue. This discovery matters because it shows that the sugar chains on biglycan normally prevent elastic fiber formation, and removing them could be a way to improve how blood vessels heal after injury by restoring elasticity rather than ending up stiff and scarred.

Plain English
The American Vascular Association/Lifeline Foundation celebrated 20 years of supporting young doctors who want to research blood vessel diseases, having given out 182 fellowships and awards during that time. The organization was created in 1986 to help early-career vascular surgeons develop their research skills and advance their medical careers. Now the foundation is raising money for an endowment to continue this work into the future.

Plain English
Researchers wrapped baboon arteries with plastic material to see if they could shrink thickened artery walls, testing whether increased blood flow would help or hurt this process. Wrapping the arteries—especially tightly—caused the artery walls to shrink by 28-45% after 28 days, and this worked equally well whether blood flow was normal or doubled. This matters because arterial thickening is a major problem after surgery and in disease, and if doctors can deliberately shrink these thickened areas using a simple wrapping technique, they might have a new way to treat patients without drugs.

Plain English
Researchers reviewed a new way to treat clogged blood vessels: instead of trying to prevent blockages from forming, they propose shrinking blockages that have already developed by killing the cells that make up the blockage and breaking down the scar tissue around them. Early experiments show this approach works—antibodies that block certain growth signals shrank blockages in artificial grafts, and blood pressure medications triggered the walls of arteries to shrink in animal studies. This matters because one-third of all reconstructed blood vessels eventually narrow, and treating only the vessels that actually develop problems (rather than trying to prevent all of them) could be a simpler and more practical solution.

Plain English
Researchers analyzed 1,404 leg bypass surgeries performed to restore blood flow in patients with severe circulation problems and found that 39% of patients developed wound complications after surgery, most commonly infections or bleeding at the incision site. Women and patients taking blood-thinning medications had higher rates of these complications, and patients who developed wound problems were more likely to lose their limb or die within a year, even though the complications didn't affect whether the bypass graft itself continued working. The study found that wound complications increased hospital stays by about a week per patient over the first year and raised overall medical costs, suggesting doctors should pay special attention to preventing these complications in female patients and those on anticoagulants.

Plain English
Researchers studied 1,404 patients who had leg bypass surgery using their own veins to save limbs threatened by poor circulation, and identified which surgical choices affected whether the grafts remained open and working. They found that using smaller veins (less than 3.5 millimeters) or veins other than the saphenous vein significantly increased the risk of graft failure within 30 days and at one year, and also meant patients needed more follow-up procedures and longer hospital stays. The findings matter because surgeons can now identify high-risk cases upfront—when they have to use smaller or lower-quality veins—and plan for more aggressive monitoring and earlier intervention to catch problems before the graft fails completely.

Plain English
Researchers compared two methods for fixing failing leg blood vessel grafts: traditional surgery versus catheter-based procedures (threading a tool through blood vessels). Surgery worked better overall—75% of surgical repairs lasted a year without needing another procedure, compared to 56% for catheter procedures—especially for completely blocked grafts. Both methods had similar hospital stays and quality of life outcomes, but catheter procedures required more repeated fixes over time to keep working, meaning they didn't last as long as surgery. For doctors choosing how to fix a failing graft, surgery is the more durable option, though catheter procedures offer a quicker, less invasive alternative when the graft is only partially blocked rather than completely blocked.

Plain English
Researchers evaluated a funding program designed to help vascular surgeons become active researchers by supporting their work from 1999 to 2005. The program was successful: about half of applicants received funding, and the surgeons who got these grants went on to publish multiple peer-reviewed papers each year and advance their careers—most received promotions and eventually secured their own independent research funding.

Plain English
Researchers followed 1,404 patients who had leg bypass surgery to restore blood flow to critically diseased limbs and measured how their quality of life changed before and after surgery. Patients reported major improvements in their ability to be active, manage pain, and feel emotionally better at both 3 months and 12 months after surgery, though diabetic patients and those who had complications showed smaller gains. The surgery successfully improved patients' quality of life, and these improvements lasted at least a year.

Plain English
Researchers analyzed 1,404 patients who had surgery to restore blood flow to dying legs and tracked how much hospital care they needed over the next year. They found that patients with severe tissue damage needed significantly longer hospital stays (nearly 10 days versus 6 days) and more readmissions than patients with less severe disease, and this pattern held true throughout the year. Complications with the surgical graft—like blockages or clots—also increased hospital needs, though other health problems like kidney failure requiring dialysis were equally or more important in determining how much care patients ultimately required.

Plain English
Doctors sometimes use synthetic patches to repair carotid arteries (the major blood vessels in the neck) after removing blockages, and while this procedure reduces stroke risk, the synthetic material can occasionally become infected. This report describes one patient who developed this rare infection and reviews what's known about treating it. The good news is that surgical removal of the infected patch, while serious, can be done safely with low rates of death and stroke.

Plain English
Researchers tested whether a drug called edifoligide could prevent blood vessel grafts from failing after surgery to restore blood flow to diseased legs in 1,404 patients—treating the grafts with the drug or a placebo before implanting them. The drug didn't reduce the need for repeat surgery or amputation, but it did modestly improve how long grafts stayed open if they needed a second intervention (83% versus 78% at one year). The drug didn't work well enough to justify its use, since it failed to achieve the main goal of preventing graft failure and the need for additional procedures.

Plain English
Researchers placed synthetic grafts in baboons and then increased blood flow through them, which caused the thick inner lining of the grafts to shrink away. They discovered that high blood flow triggered cells in the grafts to produce a protein called BMP4, which stopped smooth muscle cells from multiplying and caused them to die—explaining why the graft lining shrank. BMP4 appears to be the main driver of this shrinkage process, and blocking it reversed the effect. --- **Why it matters:** This finding could lead to better synthetic blood vessel grafts that last longer, since understanding what causes them to deteriorate is the first step toward preventing it.

Plain English
Researchers studied how a protein called PDGF makes smooth muscle cells in blood vessels grow and multiply, and discovered that PDGF actually works by triggering a second protein called FGF to do the real job of spurring cell growth. This matters because understanding this hidden two-step process could help doctors prevent restenosis—the dangerous re-narrowing of arteries after procedures like stent placement or angioplasty.

Plain English
Researchers reduced a protein called versican in smooth muscle cells and found this change made the cells produce elastic fibers instead of promoting cell growth and migration—the opposite of what normally happens after blood vessel injury. When they implanted these modified cells into injured rat arteries, the vessels developed organized, elastic tissue rather than the thick, scarred buildup that typically occurs. This matters because it could lead to better treatments for atherosclerosis and restenosis (when arteries re-clog after angioplasty), potentially preventing heart attacks and strokes.

Plain English
Researchers studied 1,404 patients undergoing leg bypass surgery for severe circulation problems to see what medicines they were taking and what heart-related complications they experienced after surgery. They found that many patients weren't on protective medications before surgery—one-third weren't on blood thinners, half weren't on cholesterol drugs, and half weren't on beta-blockers—though hospitals did start more patients on these drugs during their stay. Patients over 75, those with prior heart attacks, and those on dialysis had the highest risk of dying, having a heart attack, or having a stroke after surgery, but those who took beta-blockers and cholesterol drugs had better outcomes. The study also revealed that African-American patients were less likely to receive blood-thinning medications, and patients treated at university hospitals received more complete medical treatment overall. This matters because many high-risk leg surgery patients aren't getting proven medications that

Plain English
Researchers studied how a protein called MMP-9 affects the ability of muscle cells to squeeze and contract collagen (a structural material in blood vessels), which is what happens during dangerous vessel narrowing after angioplasty. They found that MMP-9 has a surprising dual role: at low levels it actually increases contraction, but at high levels it prevents it—and this effect has nothing to do with MMP-9's known ability to break down proteins. This matters because it explains why MMP-9 can protect against vessel re-narrowing after angioplasty and could lead to new treatments that exploit this protein's protective effect.

Plain English
Researchers studied how thrombin (a blood-clotting protein) causes muscle cells in blood vessels to multiply and move around—a process that can lead to dangerous buildup inside arteries. They found that thrombin triggers these cells to release a growth factor called bFGF, which then activates two receptor proteins (syndecan-4 and FGFR-1) that work together to make the cells divide and migrate. This matters because understanding exactly how thrombin causes blood vessel cells to proliferate could lead to new drugs that block this process and prevent heart attacks and strokes caused by arterial blockages.

Plain English
Researchers tested a new drug called edifoligide on vein grafts used to restore blood flow to patients' legs with severe circulation problems. The drug was designed to prevent the grafts from narrowing and failing—a problem that currently happens to about half of all vein grafts within five years—by stopping the overgrowth of muscle cells inside the vessel wall. In this large study of 1,400 patients, half received the new drug treatment applied directly to their vein graft before surgery, while half did not, and researchers tracked whether their grafts remained open and functional at 12 months. The results will show whether edifoligide can significantly improve survival rates of vein grafts, which would help patients avoid repeat surgeries or amputation.

Plain English
Researchers implanted synthetic blood vessel grafts in baboons and discovered that the tissue layer growing inside these grafts changes its composition depending on blood flow speed—normal flow causes a buildup of spongy, water-absorbing molecules (like versican), while high-speed flow triggers the breakdown and loss of these same molecules, causing the overgrown tissue to shrink back down. This matters because excessive tissue growth inside synthetic grafts is a major reason these implants fail in patients, and understanding how blood flow controls this growth could lead to new treatments that either prevent the dangerous buildup or trigger its reversal.

Plain English
Researchers studied how a protein called PDGF-BB makes muscle cells in blood vessels multiply, and discovered it works by triggering the release of another protein called bFGF that then activates a receptor called FGFR-1. When they blocked bFGF or FGFR-1 in their experiments, the cells stopped multiplying in response to PDGF-BB, proving this chain of events was essential. This matters because understanding how blood vessel muscle cells multiply could lead to treatments for conditions like atherosclerosis and restenosis (when arteries re-narrow after stent placement), both driven by excessive muscle cell growth in vessel walls.

Plain English
Researchers injured blood vessels in rats' necks and then blocked two natural protective substances—nitric oxide and prostaglandins—to see what would happen. Blocking both substances together caused the blood vessels to thicken much more severely than normal, while blocking just one had little effect. This matters because it shows that these two protective substances work together to prevent dangerous thickening of blood vessels, and that certain medications blocking these pathways could potentially make heart and stroke problems worse by removing this natural protection.

Plain English
Researchers studied a protein called VASP that controls whether cells in blood vessels grow or stop growing, focusing on two specific spots on the protein that can be chemically modified. They found that modifying one spot (serine157) slows cell growth, while modifying the other spot (serine239) speeds it up and makes cells resistant to a growth-stopping signal called nitric oxide. This matters because nitric oxide naturally prevents blood vessel cells from growing too much, which is important for keeping arteries healthy—and this research reveals exactly how VASP interferes with that protective process, potentially opening new ways to treat diseases like heart disease and atherosclerosis where blood vessel cells grow uncontrollably.

Plain English
Researchers injured arteries in baboons and tested whether blocking a growth protein called PDGF receptor-beta could prevent excessive tissue buildup—a common problem after blood vessel injuries in humans. Blocking this protein worked remarkably well in the first two weeks, stopping both the inner and outer layers of the artery from growing too much, but the effect weakened by week four, suggesting the treatment might not work as a long-term solution. This finding matters because baboons are much closer to humans than the rats typically used in these studies, so it warns doctors that a promising treatment might fail over time in actual patients.

Plain English
Researchers studied how two immune molecules (IL-1beta and PDGF-BB) affect muscle cells in blood vessel walls, specifically whether they move from one layer to another—a process that happens after blood vessels are injured and can lead to dangerous blockages. They found that IL-1beta actually blocks the migration-promoting effects of PDGF-BB by triggering the production of a protective substance called COX-2, which prevents these muscle cells from moving. This matters because it suggests the body has a natural brake system to prevent excessive blood vessel damage after injury; understanding this mechanism could lead to better treatments for heart disease and stroke.

Plain English
Researchers found that certain enzymes called MT-MMPs, which are produced by blood vessel cells, can break apart a key protein called FAK that normally holds cells together. When these enzymes were overexpressed in cells, the cells lost their grip on surrounding tissue and moved around more easily—changes that could contribute to dangerous conditions like heart disease and stroke. Blocking these enzymes with a drug prevented the damage to FAK and restored the cells' ability to stick together, suggesting that controlling these enzymes might be a way to treat diseases where blood vessel cells become unstable.